Quest Diagnostics Incorporated (DGX) Stock Price & Analysis
Quest Diagnostics Incorporated (DGX) closed at USD 243.28 on Thursday, October 22, 2026, up 1.82% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 238.93; the Oct 22, 2026 session ranged USD 226.5–246 on volume of 1,685,990 shares. Market capitalization is $26.85B, with a 52-week range of USD 171.18–248.84 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 08:36 UTC.
Also available as compact Markdown for AI agents: nexqual.com/DGX.md
Latest Earnings Results (DGX)
Quest Diagnostics Incorporated (DGX) reported Q3 2026 results on Oct 22, 2026, 6:49:59 AM ET: adjusted EPS $3.00 vs. estimate $2.87 (beat), revenue $3.10B vs. estimate $3.05B (beat). Guidance: Full year 2026 revenue expected between $12.065 billion and $12.105 billion, with adjusted diluted EPS between $11.25 and $11.35. Source: SEC 8-K filing. Nexqual published it 50 seconds after release. Read the SEC filing.
| Fiscal period | EPS (reported) | Revenue | Released | Source |
|---|---|---|---|---|
| Q3 2026 | $3.00 (adjusted (non-GAAP) diluted) | $3.10B | Oct 22, 2026, 6:49:59 AM ET · on Nexqual +50 seconds | SEC 8-K filing |
Reported actuals captured by Nexqual from SEC 8-K filings and company press releases; each figure confirmed by two independent extraction methods.
Key facts (DGX)
- Last four reported quarters (through Jun 30, 2026): revenue $11.6B, net income $1.06B (9.2% margin), free cash flow $1.35B (SEC filings).
- Valuation: P/E 25.3x (avg 19.2x at the last 3 fiscal year-ends), EV/EBITDA 14.4x, net debt $5.02B.
- 2 of 80 tracked superinvestors hold DGX (13F, Q2 2026): 0 new, 1 added, 1 reduced, 0 unchanged.
- Analysts: Buy (mean 2.35 on a 1–5 scale) (17 analysts), mean target USD 254.73 (range 235–275).
- Total return with dividends: 1Y +35.0% vs S&P 500 +14.9%; 5Y +82.9% vs S&P 500 +80.3%.
- Next earnings: 2026-10-22, EPS estimate USD 2.68, revenue estimate $3.04B.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (DGX)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $10.8B | $9.88B | $9.25B | $9.87B | $11.0B | $11.6B |
| Gross profit | $4.21B | $3.43B | $3.05B | $3.24B | $3.67B | — |
| Operating income | $2.38B | $1.43B | $1.26B | $1.35B | $1.56B | $1.63B |
| Net income | $2.00B | $946M | $854M | $871M | $992M | $1.06B |
| EPS (diluted) | $15.55 | $7.97 | $7.49 | $7.69 | $8.75 | — |
| Free cash flow | $1.83B | $1.31B | $864M | $909M | $1.36B | $1.35B |
| Gross margin | 39.0% | 34.7% | 33.0% | 32.9% | 33.2% | — |
| Operating margin | 22.1% | 14.4% | 13.6% | 13.6% | 14.1% | 14.1% |
| Net margin | 18.5% | 9.6% | 9.2% | 8.8% | 9.0% | 9.2% |
| Revenue growth | +14.3% | -8.4% | -6.4% | +6.7% | +11.8% | — |
| Cash + short-term investments | $872M | $315M | $686M | $549M | $420M | — |
| Total debt | $4.01B | $3.98B | $4.71B | $6.22B | $5.67B | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (DGX)
P/E 25.3x · P/S 2.3x · EV/EBITDA 14.4x · EV/Sales 2.8x · P/FCF 19.9x · P/B 3.6x · FCF yield 5.02% · Earnings yield 3.96% · Dividend yield (paid, TTM) 1.35% · Net debt $5.02B · EV $31.9B
P/E at fiscal year-ends: Dec 2025 19.8x, Dec 2024 19.6x, Dec 2023 18.2x.
Superinvestors (SEC 13F-HR, Q2 2026) (DGX)
2 of 80 tracked investors hold DGX. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Christopher Davis | Davis Advisors | 1.42% | $330M | Reduced -3.8% |
| First Eagle Investment | First Eagle Investment Management | <0.01% | $1.6M | Added +153.5% |
Analysts (DGX)
Consensus Buy (mean 2.35 on a 1–5 scale), 17 analysts; mean target USD 254.73 (low 235, high 275).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-07 | Barclays | Target raised | Overweight | $250 → $260 |
| 2026-09-21 | Truist Securities | Target raised | Hold | $250 → $260 |
| 2026-09-08 | UBS | Target raised | Neutral | $232 → $245 |
| 2026-07-28 | JP Morgan | Target raised | Neutral | $220 → $250 |
| 2026-07-25 | UBS | Target raised | Neutral | $220 → $232 |
| 2026-07-24 | Mizuho | Target raised | Outperform | $235 → $260 |
| 2026-07-24 | Truist Securities | Target raised | Hold | $225 → $250 |
| 2026-07-24 | Barclays | Target raised | Overweight | $230 → $250 |
| 2026-07-24 | Baird | Target raised | Neutral | $236 → $255 |
| 2026-07-13 | Baird | Target raised | Neutral | $232 → $236 |
Total return (dividends reinvested) (DGX)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +35.0% | +82.9% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +35.1% | +12.8% |
| Volatility (annualized) | 23.7% | 21.5% |
| Max drawdown | -11.6% (Feb 2026→May 2026) | -28.3% (Dec 2021→Sep 2022) |
DGX revenue by business segment (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| DIS business | $2.98B | 97.9% | +10.3% |
| All other operating segments | $65.0M | 2.1% | +4.8% |
| Total revenue | $3.04B | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
DGX suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | Alphabet (Google) (GOOGL) | “In 2025, we announced a collaboration with Google to use Google Cloud's data analytics and generative AI to help us streamline our data management, improve data analytics, and personalize the experiences we deliver to patients, providers, and other customers.” |
Quoted from the company's 10-K filed Feb 26, 2026.
DGX analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Dec 2026) | $2.68 | $2.66 | +0.8% | $3.04B | 12 |
| Next quarter (ends Mar 2027) | $2.73 | $2.73 | -0.2% | $3.03B | 10 |
| Current fiscal year (ends Dec 2026) | $11.27 | $11.07 | +1.8% | $12.06B | 14 |
| Next fiscal year (ends Dec 2027) | $12.00 | $11.94 | +0.6% | $12.60B | 16 |
DGX options: expected move
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 28 | 25.5% | ±5.9% |
| Dec 18, 2026 | 56 | 25.8% | ±8.3% |
| Feb 19, 2027 | 119 | 25.2% | ±11.6% |
| May 21, 2027 | 210 | 25.1% | ±15.3% |
30-day implied volatility 23.9% vs 24.6% realized over the last 30 trading days. Put/call ratio (volume) 4.17. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 08:36 UTC)
| Price | USD 243.28 |
|---|---|
| Change | ▲ 1.82% (up) |
| Previous Close | USD 238.93 |
| Open | USD 226.5 |
| Day Range | USD 226.5 – 246 |
| 52-Week Range | USD 171.18 – 248.84 |
| Volume | 1,685,990 shares |
| Market Cap | $26.85B |
| Exchange | NYQ |
Technical Analysis (DGX)
Nexqual's technical model rates DGX "BUY" based on 5 bullish and 2 bearish signals across 127 daily candles, as of October 23, 2026 at 08:36 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 61.48 (neutral) |
| vs SMA50 | Above (USD 237.49) |
| MACD | 0.69 (positive) |
Analyst Ratings (DGX)
Wall Street analysts rate DGX "Buy" based on 17 analysts, with a mean price target of USD 254.73 (range USD 235–275), per Nexqual as of October 23, 2026 at 08:36 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 17 |
| Mean Target | USD 254.73 |
| High Target | USD 275 |
| Low Target | USD 235 |
| Buy / Hold / Sell | 9 / 8 / 0 |
Earnings (DGX)
| Next Earnings Date | 2026-10-22 |
|---|---|
| EPS Estimate | USD 2.68 |
| Revenue Estimate | $3.04B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-09-30 | USD 3 vs est 2.87 ▲ beat |
| 2026-06-30 | USD 3.12 vs est 2.82 ▲ beat |
| 2026-03-31 | USD 2.5 vs est 2.37 ▲ beat |
| 2025-12-31 | USD 2.42 vs est 2.36 ▲ beat |
Source: Nexqual, October 23, 2026 at 08:36 UTC.
Financials & Fundamentals (DGX)
| Total Revenue | $11.56B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +10.20% |
| Gross Margin | +33.19% |
| Operating Margin | +15.25% |
| Profit Margin | +9.19% |
| ROE | +14.60% |
| Debt / Equity | 0.81 |
| Current Ratio | 1.59 |
| Total Cash | $626.00M |
| Total Debt | $6.40B |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | $1.35B (11.7% of revenue) |
Source: Nexqual, October 23, 2026 at 08:36 UTC.
Financial Health Score (DGX)
Nexqual rates Quest Diagnostics Incorporated's overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 08:36 UTC.
| Growth | Solid — Revenue +12% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 33%, operating 15% (last 12 months) |
| Balance Sheet | Mixed — $626M cash and investments vs $5.64B debt (Jun 2026, SEC) |
| Cash Flow | Solid — FCF $1.35B (last 4 quarters to Jun 2026, SEC), 12% margin |
| Efficiency | Mixed — ROE 15%, ROA 6.4% |
Ownership (DGX)
| Insider Ownership | +0.43% |
|---|---|
| Institutional Ownership | +98.76% |
| Shares Outstanding | 110.37M |
| Float | 109.81M |
| Short % of Float | +3.11% |
Source: Nexqual, October 23, 2026 at 08:36 UTC.
Leadership (DGX)
Quest Diagnostics Incorporated is led by James E. Davis, Chairman, CEO & President, per Nexqual as of October 23, 2026 at 08:36 UTC.
| Chairman, CEO & President | James E. Davis |
|---|---|
| Executive VP & CFO | Sam A. Samad |
| Executive Vice President of Regional Businesses | Catherine T. Doherty |
| Senior Vice President of Clinical Solutions | Karthik Kuppusamy |
| Vice President of Investor Relations | Damini Chokshi |
Major Backers & Investors (DGX)
Notable institutional backers of Quest Diagnostics Incorporated include Price (T.Rowe) Associates Inc, Boston Partners, JPMorgan, according to Nexqual as of October 23, 2026 at 08:36 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Price (T.Rowe) Associates Inc | 4.93% |
| Boston Partners | 4.3% |
| JPMorgan | 3.19% |
| Morgan Stanley | 2.23% |
| Edgepoint Investment Group Inc. | 2.04% |
| Fidelity | 1.3% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 12.1% |
| BlackRock | 8.4% |
| State Street | 5% |
| Geode Capital | 2.84% |
Source: Nexqual, October 23, 2026 at 08:36 UTC.
From Quest Diagnostics Incorporated's Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- In 2025, our Collaborative Lab Solutions (formerly known as Professional Laboratory Services) offering generated approximately $800 million in revenues and management fees supporting hospitals in the operation of their own labs.
- We drive growth by: •offering an industry-leading menu of testing and other services; •collaborating with healthcare providers and partners to leverage our broad access; •leveraging our data assets and services to improve population health and enable value-based care; and •continuously improving our quality and efficiency by leveraging the Quest Management System and by embracing innovative technologies, such as automation and artificial intelligence ("AI").
- In 2025, we generated approximately $1.2 billion in revenue from "reference testing," where we perform testing that hospitals do not perform in their own in-hospital labs. •Helping hospitals operate their labs more efficiently.
- In 2025, certain Advanced Diagnostics™ test offerings within five clinical areas – oncology, cardiometabolic and endocrine, brain health, autoimmune, women's health and genetics – generated over $1 billion in revenues on double-digit revenue growth.
Partnerships
- In 2025, we announced a collaboration with Google to use Google Cloud's data analytics and generative AI to help us streamline our data management, improve data analytics, and personalize the experiences we deliver to patients, providers, and other customers.
- We collaborate with partners and customers across the healthcare ecosystem to help create a healthier world.
Legal & Regulatory Risks (Item 1A, quoted)
- We are subject to numerous legal and regulatory requirements governing our activities, and we may face substantial fines and penalties, and our business activities may be impacted, if we fail to comply.
- Our business and operations could be adversely impacted by the FDA's approach to regulation.
- Failure to accurately bill for our services, or to comply with applicable laws relating to billing government healthcare programs, could have a material adverse effect on our business.
- We are subject to numerous political (including geopolitical), legal, operational and other risks as a result of our international operations which could impact our business in many ways.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LH | Labcorp Holdings Inc. | USD 329.93 | ▲ 1.91% |
| GH | Guardant Health, Inc. | USD 162.94 | ▼ 2.23% |
| MTD | Mettler-Toledo International, I | USD 1,684.64 | ▲ 0.4% |
| MEDP | Medpace Holdings, Inc. | USD 653.96 | ▼ 1.29% |
| RVTY | Revvity, Inc. | USD 157.36 | ▲ 0.48% |
| ILMN | Illumina, Inc. | USD 269.4 | ▼ 4.76% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 08:36 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt